EMN 2021 | Targeting CXCR4 in Waldenström’s macroglobulinemia
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the significance of CXCR4 in Waldenström’s macroglobulinemia. Mutations in CXCR4 promote enhanced MAPK 1/2 signalling, leading to sustained survival signalling for cancer cells, and can be used to predict response to BTK inhibitors. Dr Treon describes how CXCR4 may provide a therapeutic target for the treatment of Waldenström’s macroglobulinemia. In particular, Dr Treon highlights the CXCR4 targeting monoclonal antibody therapy, ulocuplumab, which is being trialled with ibrutinib in a Phase I/II study (NCT03225716), and mavorixafor, an oral selective antagonist of the CXCR4 receptor, which is being investigated in a Phase Ib trial (NCT04274738). This interview took place during the 2021 European Myeloma Network (EMN) congress.
Disclosures
Steven Treon, MD, PhD, has received research support from Abbvie/Pharmacyclics, Beigene, BMS and Eli Lilly; and has received consultancy fees from Janssen, Abbvie/Pharmacyclics, Beigene, BMS and X4.
